

Title 1 D:V Identify the study as developing and/or validating a multivariable prediction model, the target population, Abstract Title Abstract 2 D:V Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions. Abstract Introduction Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models. Introduction, paragraph 1-4 Background and objectives 3a D:V Specify the objectives, including whether the study describes the development or validation of the model or both. Introduction, paragraph 1-4 We therefore aimed to investigate if urinary LAM detection, along with other clinical variables readily available in high-burden settings, could be used to pedictive patients admitted to hospital and diagnosed with TB patients were at high risk of early mortality in, and to externally validate the predictive tool." Methods 4a D:V Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable. Methods, paragraph 1 (development), paragraph 10 (validation) Source of data 5a D:V Specify the key study dates, including start of accrual; and, if applicable, end of follow- up. Methods, paragraph 1 (development	Section/Topic	Item		Checklist Item	Page
Title 1 UV and the outcome to be predicied. Title Abstract 2 D/V Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, and the outcome to be predicide. Abstract Abstract Inroduction 3a D/V Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models. Introduction, paragraph 14 Background and objectives 3b D/V Specify the objectives, including whether the study describes the development or validation of the model or oboth. Wet therefore sime do investigate if urinary LAM detection, along with other clinical variables readily araitable in high-hurden stering, could be tend to or oboth. Methods For the development and validation data sets, if applicable. Methods, paragraph 1 (development), paragraph 10 (validate). Source of data 4a D/V Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately (validation). Methods, paragraph 1 (development), paragraph 11 (LAM RCT recriment occurred between January 2013 and October 2015 and September 2017) and Methods, paragraph 1 (cobote 2015 and September 2017) and Methods, paragraph 1 (cobote 2015 and September 2017) and Methods, paragraph 1 (cobote 2015). Participants 5b D/V Specify t	Title and abstract				
Austral 2 0.v Statistical analysis, results, and conclusions. Austral Introduction 3a D;V Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models. Introduction, paragraph 1.4 Background and objectives 3b D;V Specify the objectives, including whether the study describes the development or validation of the model or both. "We therefore aimed to investigate if urinary LAM disclosed with other clinical variables readily available in high-burden settings, could be used to predict with All Purceptite patients were at high risk development or validation of the model or both. Methods D:V Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately (validation data sets, if applicable. Methods, paragraph 11 (Abro Dostite) pariate samply validate the predictive tool." Source of data 4a D;V Specify the key study data, including start of accrual; and, if applicable, end of follow- up. Methods, paragraph 11 (Abro Dostite) Pariate and Methods, paragraph 1 Participants 5a D;V Specify the key study data, including start of accrual; and, if applicable, end of follow- up. Methods, paragraph 1 (hospital cohort) were and October 2015 and Stard 1) Participants 5a D;V Specify the key st	Title	1	D;V	and the outcome to be predicted.	Title
3a D:V Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models. Introduction, paragraph 1.4 Background and objectives 3b D:V Specify the objectives, including whether the study describes the development or validation of the model or both. Introduction, paragraph 4 We therefore aimed to investigate if urmary LAM or both. Specify the objectives, including whether the study describes the development or validation of the model or both. We therefore aimed to investigate if urmary LAM we therefore aimed to investigate if urmary LAM or both. Methods D:V Specify the objectives, including whether the study describes the development or validation of the model or both. Methods. We therefore aimed to investigate if urmary LAM we therefore aimed to investigate if urmary LAM setternal and diagnosed with TB patients admitted to hospital and diagnosed with TB patients admitted to hospital and diagnosed with TB patients admitted to hospital and diagnosed with TB patients were analysis Source of data 4a D:V Specify the key study dates, including start of accrual; and if applicable, end of follow- up. Methods, paragraph 1 (Lottober 2015 and September 2017) and Methods, paragraph 1 (LAM Scriptraph 2 Participants 5a D:V Specify key elements of the study setting (e.g., primary care, secondary care, general population) Methods, paragraph 3	Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Abstract
Source of data 4 D:V validating the multivariable prediction model, including references to existing models. Introduction, paragraph 1 Background and objectives 3b D:V Specify the objectives, including whether the study describes the development or validation of the model Introduction, paragraph 1 Methods	Introduction				
Background and objectives Jb D:V Specify the objectives, including whether the study describes the development or validation of the model or both. "We therefore aimed to investigate if urinary LAM detection, along with other clinical variables readily waiiable in high-burden settings, could be used to predict which HU-positive patients admitted to hospital and diagnosed with TB patients were at high risk of early mortality in, and to externally validate the predictive tool." Methods Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development, paragraph 1 (development), paragraph 1 (development), paragraph 1 (r the development and validation data sets, if applicable. Methods, paragraph 1 (development), (validate the predictive tool." Source of data 4a D:V Specify the key study dates, including start of accrual; and if applicable, end of follow- up. Methods, paragraph 1 (development), paragraph 1 (Development), paragraph 11 (LAM RCT recruitment occurred between January 2013 and October 2014, and the MSF cohor to between October 2013 and August 2015.) Participants 5a D:V including number and location of centres. Methods, paragraph 1 (hoctob, paragraph 1 (Methods, paragraph 3) Methods, paragraph 3 Outcome 6a D:V Clearly define the outcome that is predicted by the prediction model, including how and when assessed. Methods, paragraph 3. Methods, paragraph 3. Predictors 6b D:V		3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Introduction, paragraphs 1-4
background and objectives 3b D _V Specify the objectives, including whether the study describes the development or validation of the model or both. detection, along with other clinical variables readily predict which HIV-positive patients admitted to predict which HIV-positive patients admitted to predict which HIV-positive patients were at high risk of early mortality in, and to externally validate the predictive tool." Methods A D _V Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable. Methods, paragraph 1 (development), paragraph 10 (validation) Source of data 4a D _V V Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow- up. Methods, paragraph 1 (October 2015 and September 2017) and Methods, paragraph 11 (LAM RCT recruitment occurred between January 2013 up. Participants 5a D _V V Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres. Methods, paragraph 1 (hospital cohort) Outcome 6a D _V V Clearly define the outcome that is predicted by the prediction model, including how and when assessed. Methods, paragraph 3 Methods, paragraph 3. Outcome 6a D _V V Report any actions to blind assessment of predictors were for predictors. Methods, paragraph 2.3 Predictors wer					Introduction, paragraph 4
Source of data 4a D;V Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable. Methods, paragraph 1 (development), paragraph 10 (validation) Source of data 4b D;V Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow- up. Methods, paragraph 1 (development), paragraph 10 (validation) Participants 5a D;V Specify key elements of the study setting (e.g., primary care, secondary care, general population) Methods, paragraph 1 (hospital cohort) and October 2013 and August 2015.) Participants 5a D;V Specify key elements of the study setting (e.g., primary care, secondary care, general population) Methods, paragraph 1 (hospital cohort) Outcome 6a D;V Give details of treatments received, if relevant. Methods, paragraph 3 Outcome 6a D;V Report any actions to blind assessment of the outcome to be predicted. NA Predictors 7a D;V Report any actions to blind assessment of predictors for the outcome and other predictors. Methods, paragraph 3. Methods, paragraph 4.5 Now and when they were measured. NA NA NA Outcome Na <td>Зb</td> <td>D;V</td> <td></td> <td>detection, along with other clinical variables readily available in high-burden settings, could be used to predict which HIV-positive patients admitted to hospital and diagnosed with TB patients were at high risk of early mortality in, and to externally validate the</td>		Зb	D;V		detection, along with other clinical variables readily available in high-burden settings, could be used to predict which HIV-positive patients admitted to hospital and diagnosed with TB patients were at high risk of early mortality in, and to externally validate the
Matrix D,V for the development and validation data sets, if applicable. (validation) Source of data 4b D,V Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow- up. Methods, paragraph 1 (October 2015 and September 2017) and Methods, paragraph 11 (LAM, RCT recruitment occurred between January 2013 and October 2014, and the MSF cohort between October 2014 and the MSF cohort between October 2013 and August 2015.) Participants 5a D,V Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres. Methods, paragraph 1 (hospital cohort) 5b D,V Describe eligibility criteria for participants. Methods, paragraph 3 0utcome 6a D,V Clearly define the outcome that is predicted by the prediction model, including how and when assessed. Methods, paragraph 3 0utcome 7a D,V Report any actions to blind assessment of the outcome to be predicted. NA Predictors 7a D,V Report any actions to blind assessment of predictors for the outcome and other predictors. Methods, paragraph 3-2 Sample size 8 D,V Report any actions to blind assessment of predictors for the outcome and other predictors. Methods, paragraph 3-2 Nethods,	Methods				
Source of data Participants $4b$ D_rV Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow- up.September 2017) and Methods, paragraph 11 (LAM, RCT recruitment occurred between January 2013 and October 2014, and the MSF cohor between October 2013 and August 2015.)Participants $5a$ D_rV Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.Methods, paragraph 1 (hospital cohort) bb D_rV Describe eligibility criteria for participants.Methods, paragraph 2 bc D_rV Give datais of treatments received, if relevant.Methods, paragraph 3 $Outcome$ $6a$ D_rV Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.Methods, paragraph 4.5Predictors $7b$ D_rV Report any actions to blind assessment of predictors for the outcome and other predictors.Methods, paragraph 3.5Sample size8 D_rV Report any actions to blind assessment of predictors for the outcome and other predictors.Methods, paragraph 3.5Missing data9 D_rV Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation, with details of any imputation method.Methods, paragraph 6.7Statistical analysis methods10bDSpecify type of model, all model-building procedures (including any predictor selection), and method for internal validation.Methods, paragraph 6.7		4a	D;V		(validation)
ParticipantsSalU,Vincluding number and location of centres.Including number and location of centres.5bD;VDescribe eligibility criteria for participants.Methods, paragraph 25cD;VGive details of treatments received, if relevant.Methods, paragraph 3Outcome6aD;VClearly define the outcome that is predicted by the prediction model, including how and when assessed.Methods, paragraph 3Outcome6bD;VReport any actions to blind assessment of the outcome to be predicted.NAPredictors7aD;VClearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.Methods, paragraph 3Predictors7aD;VReport any actions to blind assessment of the outcome to be predicted.NASample size8D;VReport any actions to blind assessment of predictors for the outcome and other predictors.Methods, paragraph 2-3 Predictors all assessed prio to outcome occurringMissing data9D;VReport any actions to blind assessment of predictors for the outcome and other predictors.Methods, paragraph 2-3 Predictors all assessed prio to outcome occurringStatistical analysis methods0DDescribe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.Methods, paragraph 6-7Statistical analysis methods10bDDescribe how predictors were handled in the analyses.Methods, paragraph 6-7Statistical analysis methods	Source of data	4b	D;V		September 2017) and Methods, paragraph 11 (LAM- RCT recruitment occurred between January 2013 and October 2014, and the MSF cohort between
So D/V Describe eligibility criteria for participants. Methods, paragraph 2 5c D/V Give details of treatments received, if relevant. Methods, paragraph 3 Outcome 6a D/V Clearly define the outcome that is predicted by the prediction model, including how and when assessed. Methods, paragraph 3 "The outcome was early mortality risk at 2-months after admission" 6b D/V Report any actions to blind assessment of the outcome to be predicted. NA 7a D/V Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when assessed. Methods, paragraph 4-5 7b D/V Report any actions to blind assessment of predictors for the outcome and other predictors. Methods, paragraph 2-3 Predictors all assessed prio to outcome occurring Sample size 8 D/V Explain how the study size was arrived at. Methods, paragraph 3 - Convenience sample size Missing data 9 D/V Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation, multiple Methods, paragraph 6 & 12 Statistical analysis methods 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. </td <td rowspan="3">Participants</td> <td>5a</td> <td>D;V</td> <td>Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.</td> <td>Methods, paragraph 1 (hospital cohort)</td>	Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Methods, paragraph 1 (hospital cohort)
Outcome 6a D;V Clearly define the outcome that is predicted by the prediction model, including how and when assessed. Methods, paragraph 3 "The outcome was early mortality risk at 2-months after admission" 6b D;V Report any actions to blind assessment of the outcome to be predicted. NA Predictors 7a D;V Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured. Methods, paragraph 4-5 7b D;V Report any actions to blind assessment of predictors for the outcome and other predictors. Methods, paragraph 2-3 Predictors all assessed prio to outcome occurring Sample size 8 D;V Explain how the study size was arrived at. Methods, paragraph 3 "Convenience sample size Missing data 9 D;V Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation, with details of any imputation method. Methods, paragraph 6 & 12 Statistical analysis methods 10a D Describe how predictors were handled in the analyses. Methods, paragraph 6-7 Statistical analysis methods 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. Methods, paragraph 6-7		5b	D;V	Describe eligibility criteria for participants.	Methods, paragraph 2
Outcome6aD,VClearly define the outcome that is predicted by the prediction model, including how and when assessed.mortality risk at 2-months after admission"6bD;VReport any actions to blind assessment of the outcome to be predicted.NAPredictors7aD;VClearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.Methods, paragraph 4-57bD;VReport any actions to blind assessment of predictors for the outcome and other predictors.Methods, paragraph 2-3 Predictors all assessed prio to outcome occurringSample size8D;VExplain how the study size was arrived at.Methods, paragraph 3- Convenience sample sizeMissing data9D;VDescribe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.Methods, paragraph 6 & 12Statistical analysis methods10bDSpecify type of model, all model-building procedures (including any predictor selection), and method for internal validation.Methods, paragraph 6-7		5c	D;V	Give details of treatments received, if relevant.	Methods, paragraph 3
Predictors7aD;VClearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.Methods, paragraph 4-57bD;VReport any actions to blind assessment of predictors for the outcome and other predictors.Methods, paragraph 2-3 Predictors all assessed prio to outcome occurringSample size8D;VExplain how the study size was arrived at.Methods, paragraph 3- Convenience sample sizeMissing data9D;VDescribe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.Methods, paragraph 6 & 12Statistical analysis methods10bDSpecify type of model, all model-building procedures (including any predictor selection), and method for internal validation.Methods, paragraph 6-7	Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	
Predictors7aD;Vhow and when they were measured.Methods, paragraph 4-57bD;VReport any actions to blind assessment of predictors for the outcome and other predictors.Methods, paragraph 2-3 Predictors all assessed prio to outcome occurringSample size8D;VExplain how the study size was arrived at.Methods, paragraph 3- Convenience sample sizeMissing data9D;VDescribe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.Methods, paragraph 6 & 12Statistical analysis methods10aDDescribe how predictors were handled in the analyses.Methods, paragraph 6-7Statistical analysis methodsDSpecify type of model, all model-building procedures (including any predictor selection), and method for internal validation.Methods, paragraph 6-7		6b	D;V		NA
7b D;V Report any actions to blind assessment of predictors for the outcome and other predictors. Methods, paragraph 2-3 Predictors all assessed prior to outcome occurring Sample size 8 D;V Explain how the study size was arrived at. Methods, paragraph 3- Convenience sample size Missing data 9 D;V Explain how the study size was arrived at. Methods, paragraph 3- Convenience sample size Missing data 9 D;V Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method. Methods, paragraph 6 & 12 10a D Describe how predictors were handled in the analyses. Methods, paragraph 6-7 Statistical analysis methods 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. Methods, paragraph 6-7	Predictors	7a	D;V		Methods, paragraph 4-5
Missing data 9 D;V Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation, multiple Methods, paragraph 6 & 12 10a D Describe how predictors were handled in the analyses. Methods, paragraph 6-7 Statistical analysis methods 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. Methods, paragraph 6-7		7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	Methods, paragraph 2-3 Predictors all assessed prior to outcome occurring
Missing data 9 D, v imputation) with details of any imputation method. Methods, paragraph 6 & 12 10a D Describe how predictors were handled in the analyses. Methods, paragraph 6-7 Statistical analysis methods 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. Methods, paragraph 6-7	Sample size	8	D;V		Methods, paragraph 3- Convenience sample size
Statistical analysis methods 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for Methods, paragraph 6-7	Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Methods, paragraph 6 & 12
analysis methods 100 D internal validation.		10a	D		Methods, paragraph 6-7
		10b	D		Methods, paragraph 6-7
		10c	V	For validation, describe how the predictions were calculated.	Methods, paragraph 12



	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Methods, paragraph 8-9, 13
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	None done
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	Methods, paragraph 7 "High-, medium- and low-risk groups for mortality were then arbitrarily defined after plotting risk score against observed mortality, so the high-risk group accounted for most (>50%) deaths, and low-risk group accounted for as few deaths as possible"
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Methods, paragraph 11
Results				
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Results, paragraph 1; Figure 1
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Results, paragraph 1; Table 1
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Table 1, Figure 4
Model	14a	D	Specify the number of participants and outcome events in each analysis.	Results, paragraph 1;, Figure 1
development	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	Table 2
Model	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Table 2
specification	15b	D	Explain how to the use the prediction model.	Results, paragraph 4-6;
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	Figures 3 & 4; Results, paragraph 4, 6, 8-9
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	NA
Discussion				
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Discussion, paragraphs 9-10
Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Discussion, paragraph 11
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	Discussion, paragraphs 1-6
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	Discussion, paragraphs 5-6
Other information				
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Data statement, supplement
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	Financial Disclosure Statement

*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.